Preventive effects of Brassicaceae family for colon cancer prevention: A focus on in vitro studies
MetadataShow full item record
AuthorPeña Contreras, María Mercedes; Guzmán, Ana; Martínez Martínez, Rosario; Mesas Hernández, Cristina; Prados Salazar, José Carlos; Porres Foulquie, Jesús María; Melguizo Alonso, Consolación
Brassicaceae familyColon cancerAntitumor activityBioactive compoundsIn vitro assay
Mercedes Peña... [et al.]. Preventive effects of Brassicaceae family for colon cancer prevention: A focus on in vitro studies, Biomedicine & Pharmacotherapy, Volume 151, 2022, 113145, ISSN 0753-3322, [https://doi.org/10.1016/j.biopha.2022.113145]
SponsorshipSpanish Government RTC2019-006870-1; Junta de Andalucia P18-TP-1420; Granada University; CELLBITEC S.L.; FPU2019 grant from the Ministerio de Universidades (Spain) FPU19/06170; Spanish Government DIN2018009995B04847216; Andalusian Government AGR145 CTS-107
The emergence of adverse effects and resistance to colorectal cancer (CRC) current therapies calls for the development of new strategies aimed at both preventing and treating. In this context, functional extracts from Brassicaceae family contains abundant bioactive compounds directly related to a positive effect on human health including cancer. The main objective of this systematic review is to compile all recent studies that analyzed the in vitro antiproliferative activity of functional extracts or isolated molecules from the Brassicaceae family against CRC. A total of 711 articles published between January 2011 and May 2021 were identified. Of them, 68 met our inclusion criteria. Different standardized protocols using variable parts of plants of the Brassicaceae family resulted in diverse bioactive extracts and/or compounds. Most of them were related to isothiocyanates, which showed significant antitumor activity against CRC. These in vitro studies provide an excellent guide to direct research on the applications of plants of the Brassicaceae family to the prevention of this type of tumor. The extracts and molecules with demonstrated activity against CRC should be tested in vivo and in clinical trials to determine their usefulness in the prevention of this cancer to reduce its global incidence.